Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Crescita Therapeutics (CRRTF) held its Annual General and Special Meeting of Shareholders on June 4, 2025, at its headquarters in Laval, Quebec.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Election of Directors
Director Nominees |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
FOR |
WITHHELD |
FOR |
WITHHELD |
|
Daniel N. Chicoine |
5,432,232 |
301,172 |
|
|
Anthony E. Dobranowski |
5,455,219 |
278,185 |
|
|
John C. |
5,427,266 |
306,138 |
|
|
Deborah Shannon-Trudeau |
5,463,225 |
270,179 |
|
|
Serge Verreault |
5,490,982 |
242,422 |
|
|
Reappointment of External Auditors
Outcome |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
FOR |
WITHHELD |
FOR |
WITHHELD |
|
Ernst & Young LLP reappointed |
6,388,758 |
49,767 |
|
|
Approval of the Continuation of Crescita’s Shareholder Rights Plan
Outcome |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
FOR |
AGAINST |
FOR |
AGAINST |
|
Shareholder Rights Plan approved |
5,481,368 |
252,036 |
|
|
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.
Source: Crescita Therapeutics
View source version on businesswire.com: https://www.businesswire.com/news/home/20250605776909/en/
FOR MORE INFORMATION, PLEASE CONTACT:
Linda Kisa, CPA, CA
Vice-President, Reporting and Corporate Affairs
Email: lkisa@crescitatx.com
Source: Crescita Therapeutics Inc.